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Abstract As a biomarker of beta-amyloid, positron emis-
sion tomography (PET) amyloid imaging offers a unique
opportunity to detect the presence of this protein in the
human body during life. Besides Alzheimer’s disease (AD),
deposits of beta-amyloid in the brain are also present in other
neurodegenerative diseases associated to dementia, such as
Parkinson’s disease and dementia with Lewy bodies, as well
as in other processes affecting brain function, such as cere-
bral amyloid angiopathy, brain trauma, Down’s syndrome
and meningiomas, as shown by post-mortem pathology
studies. Furthermore, in systemic amyloidosis other organs
besides the brain are affected, and amyloid PET imaging may
be suitable for the identification of these extra-cerebral
amyloid depositions. Finally, the potential use of amyloid
PET tracer accumulation in cerebral white matter (WM) as a
marker of myelin is being investigated, leading to some
promising results in patients with WM lesions and multiple
sclerosis. In this article, a review of the ongoing research
pointing to a broader application of amyloid PET imaging in
clinical practice beyond AD is provided.
Keywords Amyloid PET  Brain trauma  Cardiac
amyloidosis  Multiple sclerosis  Cerebral amyloid
angiopathy  Down’s syndrome
Introduction
The development of 11C-PIB allowed for the first time
detection of beta-amyloid plaques in the human brain
during life using positron emission tomography (PET)
imaging. Subsequent development of 18F-labeled amyloid
PET tracers, such as 18F-florbetapir, 18F-florbetaben, 18F-
flutemetamol (all three FDA and EMA approved) and 18F-
AZD4694 has contributed to a widespread use of amyloid
PET imaging. Except for the latter, which still is an inves-
tigational compound, the approved indication is for PET
imaging of beta-amyloid neuritic plaque density in the
brains of adult patients with cognitive impairment who are
being evaluated for Alzheimer’s disease (AD) and other
causes of cognitive impairment. However, as a biomarker of
beta-amyloid, PET amyloid imaging offers a unique
opportunity to detect the presence of this protein in the
human body during life. Hence, active research has been
already initiated to investigate the potential clinical rele-
vance of the in vivo diagnosis of other conditions beyond
AD, which are known to present with beta-amyloid depo-
sitions from post-mortem pathology studies. This is the case
of other neurodegenerative diseases associated to dementia,
such as Lewy body diseases, including dementia with Lewy
bodies (DLB) and Parkinson’s disease (PD), as well as in
other processes affecting brain function, such as cerebral
amyloid angiopathy (CAA), brain trauma including trau-
matic brain injury (TBI) and chronic traumatic encepha-
lopathy (CTE), Down’s syndrome (DS), and meningiomas.
Furthermore, in systemic amyloidosis other organs besides
the brain are affected, and amyloid PET imaging may be
suitable for the identification of these extra-cerebral amy-
loid depositions. Cardiac amyloidosis (CA) is of particular
interest, since it is the main cause of mortality and mor-
bidity in systemic amyloidosis. Finally, the potential use of
amyloid PET tracer accumulation in cerebral white matter
(WM) as a marker of myelin is being investigated, leading
to some promising results in patients with WM lesions and
multiple sclerosis (MS). In this article, a review of the
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ongoing research pointing to a broader application of
amyloid PET imaging in clinical practice beyond AD is
provided. For this purpose, a PubMed search was performed
using the combination of the terms ‘‘Amyloid PET’’ or
‘‘beta-amyloid’’ and each of the following: ‘‘Parkinson’s
disease’’, ‘‘DLB’’, ‘‘CAA’’, ‘‘TBI’’, ‘‘Down’s syndrome’’,
‘‘meningiomas’’, ‘‘cardiac amyloidosis’’, ‘‘multiple sclero-
sis’’. Publications including amyloid PET imaging data in
humans were selected. Additional publications that came
out from the references of the retrieved articles were also
included. 11C-PIB was by large the most used tracer.
Despite further data with 18F-labeled amyloid PET tracers is
definitively needed, the reported relationship between 11C-
PIB and 18F-labeled amyloid PET tracers behavior [1–4],
supports the hypothesis that similar results could be
obtained with these other tracers.
Lewy body diseases: dementia with Lewy bodies
and Parkinson’s disease
Co-pathology of beta-amyloid, tau and alpha-synuclein is
present in several neurodegenerative diseases, including
AD, PD, and DLB, and some cases of multiple system
atrophy (MSA). DLB is the second most common neuro-
degenerative dementia, after AD [5]. Moreover, together
with PD, it is the most common synucleinopathy associated
with dementia. Both PD and DLB patients share pathology
findings, including cortical Lewy body accumulation/
alpha-synuclein toxicity and beta-amyloid plaques [6], and
show clinically similar manifestations. It has therefore been
hypothesized that PD patients with dementia (PDD) and
DLB may be different phenotypic expressions of the same
underlying process [7]. Some differences include the time
elapsed between the onset of Parkinsonism and the mani-
festation of dementia, which is shorter for DLB than for PD
[8]. According to post-mortem data, beta-amyloid can be
found in about one-fourth of patients with alpha-synuclein,
with the highest proportion in DLB, followed by PDD [9].
It has been hypothesized that early and significant amyloid
burden may accelerate cognitive decline in patients with
DLB [10]. However, the relative timing of these events
cannot be determined by postmortem studies, and the
clinical significance of the beta-amyloid deposits in DLB is
still unclear. In agreement with this hypothesis, Villemagne
et al. [11] found a trend to a significant correlation between
neocortical 18F-florbetaben standardized uptake value ratio
(SUVR) and time elapsed between onset of cognitive
impairment and development of the diagnostic clinical
features in DLB, which was not found in AD or fronto-
temporal lobe degeneration patients. Therefore, amyloid
PET imaging may provide some light into the conse-
quences of beta-amyloid deposition and its relationship
with cognitive decline and other clinical, demographic,
genetic, and biochemical characteristics. The level of
amyloid PET tracer binding, as well as its regional local-
ization and the relationship with clinical symptomatology
has been investigated in a series of studies including PDD
and DLB patients, in addition to AD and normal controls.
Amyloid PET imaging findings in PD are subject of an
independent article in this journal issue (Frey K). Hence,
data focused on DLB studies is provided here.
The finding of increased amyloid PET tracer uptake in
DLB patients and PDD varies across series (Table 1).
Patient characteristics and recruitment sources may account
for this variability. Patients recruited from dementia centers
suffer primarily from cognitive decline and have a higher
risk for AD, and therefore a higher frequency of positive
PET scans in DLB (85–88 %) [12] than those presenting to
movement disorder centers (33–44 %), who suffer mainly
from motor disabilities [13, 14]. No differences in 11C-PIB
uptake between PDD and DLB were found in one study
[13], but a lower 11C-PIB retention in PDD than in DLB has
been more often reported [12]. Actually, whereas it may be
difficult to differentiate PDD patients from PD patients
without dementia, who show mild 11C-PIB uptake or even
overlapping distribution volume ratios (DVRs) with con-
trols, a majority of DLB patients show similar or slightly
lower levels of 11C-PIB binding than AD, and clearly higher
than PD and PDD [12–16]. This finding has been replicated
in one study using 18F-florbetaben [11], although the pro-
portion of DLB patients with positive scan was lower (2 out
of 7 patients) (Fig. 1). However, some DLB patients do not
show beta-amyloid plaques at autopsy. In agreement with
this finding, a minority of DLB patients have shown nega-
tive 11C-PIB scans (e.g. 1 out of 8 DLB patients in [15]),
and five out of seven DLB patients in a study with 18F-
florbetaben [11]. Differences in the prevalence of neuritic
and diffuse plaques may partially explain the differential
11C-PIB retention in DLB and PDD. Both neuritic dense
core plaques and diffuse plaques are associated with DLB
[6] whereas in PDD, diffuse plaques are common and more
prevalent [17]. It has been postulated that a ‘‘pure’’ diffuse
Lewy body changes without accompanying AD neuropa-
thology changes may explain the negative scan findings in
DLB. A case of a 11C-PIB negative patient with DLB who
showed sparse beta-amyloid levels at autopsy in some brain
regions has been reported [18]. Likewise, a minority of
PDD subjects may show high cortical 11C-PIB retention,
similar to AD patients [12–14, 19, 20]. In a study comparing
characteristics of 11C-PIB positive and negative DLB
patients, Maetzler et al. [14] reported lower mini-mental
score examination (MMSE) scores, higher prevalence of
ApoE4 and females, and higher age at inclusion, onset of
parkinsonism, and onset of dementia in 11C-PIB positive
patients.
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With regard to the regional localization of amyloid PET
tracer uptake, Gomperts et al. [15] reported a higher
accumulation of 11C-PIB in the occipital lobe in DLB,
PDD and PD patients than in AD, suggesting that this
localized amyloid burden might be related to, or may be the
cause of the occipital hypometabolism frequently found in
Table 1 Summary of clinical amyloid PET results in Lewy body diseases (focus on Lewy body dementia)
References Study objective Subject sample (n, clinical
diagnosis)
Main amyloid PET results
Gomperts et al.
[15]





DLB higher uptake than PDD, comparable to AD
PDD lower uptake, comparable to PD and HC
Occipital uptake lower in AD than in DLB
Relationship of parietal uptake with visuospatial
impairment in DLB, PDD and PD
Striatal uptake related to less impaired motor
function in DLB and PDD




Differences in PIB ? and PIB -




11C-PIB - in all PD (non-demented)
11C-PIB ? in 4PDD and 4 DLB
11C-PIB ? associated with MMSE scores, ApoE4,
age, and onset of parkinsonism and dementia
Claassen et al.
[16]





All DLB increased 11C-PIB uptake
No 11C-PIB uptake in MSA
In DLB, correspondence between areas with
hypometabolism and high 11C-PIB uptake
Villemagne et al.
[11]
18F-florbetaben PET comparison in








18F-florbetaben ? in 29 % DLB, cortical binding
distribution similar to AD, but cortical uptake
lower than in AD
18F-florbetaben - in all PD
Trend for SUVR correlation time elapsed between
onset of cognitive impairment and diagnostic
clinical features only in DLB
Goemperts et al.
[19]
Relationship between 11C-PIB and
cognitive impairment in DLB
and PD





11C-PIB uptake higher in DLB than in any of the
other groups
No differences in 11C-PIB uptake across PDD, PD-
MCI, PD and HC
11C-PIB increased with age and ApoE4 in all patient
groups
DLB only PIB association with impaired cognition
Ikonomovic et al.
[18]





11C-PIB - in probable DLB, with scares beta-
amyloid plaques in less than 2 % cortical area at
autopsy
11C-PIB ? in probable AD with plaques in up to
12 % cortical area
Shimada et al.
[89]
Relationship between 11C-PIB and
cortical atrophy in DLB.




11C-PIB ? in forty percent of DLB/PDD
11C-PIB ? in all AD
11C-PIB - in all HC
11C-PIB ? DLB/PDD/AD had similar pattern of
cortical atrophy
11C-PIB - DLB/PDD had no significant cortical
atrophy
Kim et al. [24] 11C-PIB in MSA 9, MSA (without dementia)
6, MSA (with dementia)
10, HC
11C-PIB - in MSA, comparable to controls
? Positive scan, - negative scan, AD Alzheimer’s disease, DLB dementia with Lewy bodies, PD Parkinson’s disease, PDD Parkinson’s disease
dementia, MCI mild cognitive impairment, HC healthy controls, FTLD frontotemporal lobe degeneration, VaD vascular dementia, MSA multiple
system atrophy, MMSE mini-mental state examination
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18F-FDG PET scans in these patients [21]. Regional 11C-
PIB binding in the occipital and primary visual cortex in
DLB patients, as well as in other areas such as prefrontal
and parieto-temporal, have reported to correspond to
regions with hypometabolism shown in 18F-FDG PET
images [14, 16]. Some relationships of 11C-PIB uptake
patterns and clinical symptoms have been reported.
Regional amyloid deposition in the parietal (lateral and
precuneus)/posterior cingulate region in DLB, PDD, and
PD was related to visuospatial impairment [15]. Foster
et al. [13] reported an association between global and
caudate 11C-PIB increased uptake and severity of global
cognitive impairment in both DLB and PDD, but not with
other neuropsychological features. Striatal 11C-PIB reten-
tion in the DLB and PDD groups has been associated with
less impaired motor function, suggesting that the presence
of beta-amyloid in striatum of DLB and PDD patients at
autopsy [22] is not a marker of motor dysfunction, but
could be an early site for amyloid deposition in DLB [12,
14]. Interestingly, a higher 11C-PIB binding in striatum
seems to be a present in familial than in sporadic AD cases
[23]. These findings point to a clinical meaning of the
topography of beta-amyloid accumulation, hence encour-
aging the regional assessment in front of a global assess-
ment of amyloid PET tracer uptake, to gather more
information on the potential implications for diagnosis and
prognosis.
Amyloid PET imaging can also be useful in the differ-
entiation of patients with DLB and MSA, since both may
present with rapid eye movement sleep behavior disorder
and severe autonomic dysfunction, and in some cases,
MSA patients may present cognitive impairment and
dementia [24, 25]. Although the pathology hallmarks are
different for each disease (i.e. alpha-synuclein in DLB and
oligodendroglial cellular inclusions in MSA), co-pathology
coexists in 10–20 % of MSA cases. However, while
amyloid pathology is frequent in DLB, it is very rare in
MSA [26]. Preliminary amyloid PET imaging results using
11C-PIB in DLB and MSA patients have been reported.
Claassen et al. [16] found no 11C-PIB uptake in any of the
three MSA patients included in their study, but in all the
three DLB patients included. Kim et al. [24] reported no
statistically significant differences in global 11C-PIB
binding between normal controls and MSA patients, nei-
ther when comparing the subgroups of MSA patients
without and with dementia with normal controls (Table 1).
These findings suggest that amyloid PET imaging could be
helpful in the differential diagnosis in cases where DLB
and MSA may present with similar clinical symptoms.
However, one MSA patient without dementia and two
MSA patients with dementia in Kim et al. [24] series, were
found to show quantitative 11C-PIB values above the cut-
off threshold of 1.5 for 11C-PIB positivity, which might be
explained by the rare MSA cases reported with amyloid
pathology [26], and contributing to dementia in the two
latter cases. Authors proposed a longitudinal follow-up of
the 11C-PIB positive MSA patient without dementia, con-
sidering that amyloid burden is detected even in the pre-
symptomatic phase of AD [27]. Further studies with larger
patient samples and 18F-labeled amyloid tracers are needed
to establish the usefulness of amyloid PET imaging in the
differential diagnosis of DLB and MSA, and the role of
beta-amyloid deposition in the pathogenesis and clinical
course of dementia in these diseases. Future research
should be aiming to determine whether amyloid PET
imaging can help identifying which MCI patients will
progress to AD or DLB, and to clarify the potential clinical
implications of the topography of the different regional
beta-amyloid depositions in these neurodegenerative dis-
eases. Moreover, multimodal molecular imaging, allowing
the in vivo mapping of dopamine transporters, glucose
metabolism, neuroinflammation and tau, besides amyloid,
can be used to achieve an accurate pathology diagnosis and
classification in vivo.
Fig. 1 Representative 18F-florbetaben PET transaxial images over-
laid on individual coregistered MR images of a healthy control (HC)
and patients with Parkinson’s disease (PD), dementia with Lewy
bodies (DLB), mild cognitive impairment (MCI), Alzheimer’s disease
(AD), frontotemporal lobar degeneration (FTLD), and vascular
dementia (VaD). Only the DLB, MCI and AD patients show cortical
18F-florbetaben uptake in addition to the non-specific white matter
uptake visible in negative scans of HC, PD, FTLD, and VaD. The
cortical tracer uptake in DLB is lower than in AD. All images are
scaled to same SUVR maximum. This research was originally
published in JNM. Villemagne et al. [11]  by the Society of Nuclear
Medicine and Molecular Imaging, Inc
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Cerebral amyloid angiopathy
Perivascular amyloid depositions are a hallmark of CAA,
a major cause of spontaneous hemorrhagic stroke [mi-
crohemorrhages (MH), intracerebral hemorrhage (ICH))
and vascular cognitive impairment in the elderly [28].
CAA is present in about one-third of subjects 60 years or
older, and in up to 90 % of AD patients in post-mortem
studies [29]. Similarly to what happens in AD, the clinical
diagnosis of ‘‘possible’’ and ‘‘probable’’ CAA is currently
based on clinical guidelines such as the Boston opera-
tional criteria [30], but brain tissue pathology is needed
for confirmation. An accurate and early diagnosis is of
importance given the high morbidity and mortality rates
associated with ICHs [28], and the risk of vasogenic
edema associated with MH reported in clinical trials with
anti-beta-amyloid immunotherapy for AD [31]. An accu-
rate, non-invasive biomarker would also be useful in
monitoring novel drugs for CAA.
Amyloid PET tracer binding to fibrillar amyloid in
perivascular beta-amyloid depositions (hallmark of CAA)
in addition to beta-amyloid plaques in the cerebral paren-
chyma (hallmark of AD), has been reported using 11C-PIB
[32, 33] which hass been the most extensively used tracer
to investigate the potential clinical utility of amyloid
imaging in CAA (Table 2). Since the PET signal cannot
distinguish between binding in parenchymal beta-amyloid
plaques and beta-amyloid in vessel walls, and given the
high incidence of CAA in AD patients, the inclusion of
non-demented CAA patients in the amyloid PET studies is
an indirect way to minimize the effect of accompanying
AD pathology [34]. This may explain the lack of significant
differences in average cortical 18F-florbetapir SUVR found
in one study between AD cases with and without higher
CAA density [35], in contrast to the replicated finding of a
higher 11C-PIB uptake in non-demented CAA patients,
which has been consistently reported to be intermediate
between healthy controls and AD [34, 36, 37]. Interest-
ingly, the amyloid accumulation pattern seems to differ
from the AD pattern in that the occipital lobe is more
frequently affected in CAA (Fig. 2). Quantification may be
required to pick up better this different pattern than visual
assessment [38], and a higher occipital to global 11C-PIB
ratio in CAA than in AD has been a replicated finding [34,
36, 37]. Further in-vivo data supporting the feasibility for
the identification on 11C-PIB binding in vascular amyloid
include the co-localization of 11C-PIB uptake with MH as
detected by magnetic resonance imaging (MRI) [39], the
correlation with WM hyperitensities (WMH) volume in
probable CAA patients but not in AD or cognitively normal
controls [40] and the higher 11C-PIB uptake in cognitively
normal controls with lobar MH than in those without lobar
MH [41].
Amyloid PET imaging seems to have potential to predict
future hemorrhages, since new CAA-related hemorrhages
occur preferentially at sites of increased amyloid deposi-
tion as detected by 11C-PIB PET images [39]. It could also
be a marker of CAA severity, given the reported strong
correlation between global 11C-PIB retention and WMH in
CAA but not in healthy controls or AD, supporting the
hypothesis that vascular amyloid burden directly contrib-
utes to chronic cerebral ischemia [40]. Moreover, 11C-PIB
imaging could allow investigating atypical clinical courses
of patients with CAA, as suggested by the positive 11C-PIB
scan findings in two reported cases of CAA-associated
encephalopathy [42]. The diagnostic utility of amyloid PET
imaging in CAA-related symptomatic lobar intracerebral
hemorrhage has been recently investigated using 11C-PIB
[38]. A low specificity (55 %) to differentiate probable
CAA from age-matched healthy controls was found, in
consistency with the high frequency of 11C-PIB positive
scans in healthy aged controls [43, 44]. In contrast, a high
sensitivity (91 %) and negative predictive value (83 %)
were found, indicating that a negative 11C-PIB scan allows
ruling out CAA with good confidence. Replication of these
11C-PIB findings with 18F-labeled amyloid PET tracers
would foster the clinical use of amyloid PET imaging in
CAA. In particular, pathology studies similar to those
reported with 11C-PIB, to confirm a similar selectivity for
fibrillary amyloid in CAA are still needed with 18F-labeled
tracers. Future studies aiming to further define the rela-
tionship between CAA and its clinical consequences, and
investigation of the performance of novel radioligands,
selective for beta-amyloid deposit in vessel walls [45, 46]
in CAA are required to better understand the potential
benefit of amyloid imaging in clinical practice.
Brain trauma
Brain trauma is a common cause of permanent neurological
deficits, most often occurring in young people as a conse-
quence of a single, acute head contusion. Beta-amyloid
deposition has been found in 30 % of fatal TBI patients
[47], thus increasing the risk of AD. Chronic repetitive
TBI, as observed in athletes and military personnel, first
identified in boxers as dementia pugilistica [48], may
increase the risk of CTE. Neuropathologically, CTE is a
tangle-predominant disease or tauopathy, but variable
degrees of diffuse beta-amyloid deposition have been
found in about 47 % of pathology-verified CTE cases [49].
There is preliminary evidence that amyloid PET imag-
ing is suitable to detect cerebral beta-amyloid deposits in
patients with TBI, using 11C-PIB as a tracer [50, 51]
(Table 3). However, limited sample sizes and differences
in study design, including differences in the patient
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population [i.e. severity of TBI, neuropsychological status,
other brain lesions causing abnormal structural findings in
computerized tomography (CT) and MRI, age], time of
scanning after TBI, quantification and regions assessed,
highlight the need of replication in further studies. Kawai
et al. [50] examined for the first time the cerebral beta-
Table 2 Summary of clinical amyloid PET results in cerebral amyloid angiopathy
References Study objective Subject sample (n, clinical
diagnosis)
Main amyloid PET results
Johnson
et al. [90]
11C-PIB detection of CAA 6, CAA non-demented
15, HC
9, Probable AD
All CAA and AD PIB ? (DVR, visual)
11C-PIB global cortical retention in CAA higher than HCs, lower
than AD






16, Probable CAA non
demented-580 microbleed
regions on T2-MRI
11C-PIB global cortical retention in CAA higher than HCs, lower
than AD
Occipital to global 11C-PIB ratio higher in CAA than AD
Mean DVR at microbleed loci greater than at sites of simulated
lesions
DVR declined with increasing distance from the microbleed center
Ly et al.
[37]
11C-PIB in CAA and AD 12, CAA
22, NC
13, AD
11C-PIB global cortical retention in CAA higher than HVs, lower
than AD









HC with LMH higher SUVR than HC without LMH
Positive correlation between number of LMH and SUVR
Positive correlation between number of LMH and age





location and number of
future hemorrhages in
CAA (longitudinal study)
11, CAA non demented Mean DVR was greater at sites of incident bleeds than simulated
lesions
DVR declines with increasing distance from the center
Mean DVR in superior frontal/parasagittal ROI correlated with











Higher amounts of WMH in CAA than HC and AD/MCI, despite
CAA pts were younger
Strong correlation between global 11C-PIB retention and WMH in





57, Non (n = 29)-mild
(n = 28) cognitive
impairment subjects with
PIB PET and DTI
Ab deposition significantly associated with FA in fornix and
splenium of corpus callosum
Baron et al.
[38]







20, HC without cognitive
impairment (9 elderly
age-matched)
No significant difference in whole cortex or regional DVRs between
CAA and HC
4/9 aged HC and 10/11 CAA had whole cortex DVR above 95 % CL
(sensitivity 91 %, specificity 55 %)
Region/frontal or occipital ratios did not have better discriminative
value





11, Probable AD with
severe CAA
No significant differences in average cortical SUVR between AD
cases with and without higher CAA density
Sengoku
et al. [42]
CAA and encephalopathy 2, Encephalopathy with
CAA
Case 1: 11C-PIB ? in AD-like pattern (fronto-parieto-temporal,
precuneus)
Case 2: 11C-PIB ? focal uptake corresponding to subarachnoid
hemosiderosis and microbleeds
? Positive scan, - negative scan, CAA cerebral amyloid angiopathy, MH microhemorrhages, LMH lobar microhemorrhages, HC healthy
controls, MCI mild cognitive impairment, AD Alzheimer’s disease, WMH white matter hyperintensities, FA fractional anisotropy, DTI diffusor
tensor imaging, SUVR standard uptake value ratio, DVR distribution volume ratio
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amyloid deposition in a total of 12 patients at the chronic
stage after TBI (range = 5–129 months, median
54 months). TBI was severe in nine patients and moderate
in three. All patients showed some degree of neuropsy-
chological impairment, but none of them had clinical signs
of dementia. No patients had a history of repetitive mild
TBI such as contact sports or boxing. Only 3 out of the 12
patients showed positive scans consistent with presence of
beta-amyloid, thus questioning the hypothesis of progres-
sive beta-amyloid accumulation over time in the trauma-
tized brain. This finding is however consistent with
pathology studies reporting extensive beta-amyloid depo-
sition within a day, as earliest as 2 h after injury in surgi-
cally excised brain tissue after TBI [52], and absence of
beta-amyloid in long-term survivors after TBI [53]. 11C-
PIB uptake was moderate, with lower binding potential
values than those observed in two age- and MMSE score-
matched AD patient controls. There was no correlation
between 11C-PIB deposition and the severity of injury,
initial CT findings, elapsed time from the injury, and
neuropsychological test scores. Hong et al. [51] studied 15
patients with moderate to severe TBI from 3 days to 1 year
after injury. No data on patient cognitive status was pro-
vided. Significantly increased 11C-PIB DVRs and SUVRs
were found in cortical gray matter and striatum of TBI
patients as a group, but not in thalamus or WM. The dif-
ference in the results from Kawai et al. [50] study may be
explained by the shorter time elapsed in this case between
Fig. 2 Representative 11C-PIB PET images at two transaxial levels
from normal control (NC) (11C-PIB-negative), Alzheimer’s disease
(AD), and cerebral amyloid angiopathy (CAA) subjects. Compared
with AD and NC, CAA subjects had an intermediate level of global
11C-PIB retention, but compared with AD, had relatively increased
occipital retention. Microbleeds seen in this patient, shown in
coregistered gradient echo magnetic resonance images, at times
appear proximal to foci of amyloid deposition (small arrows).
Reproduced from Ann Neurol, Johnson et al. [34] 2007 with
permission from the American Neurological Association
Table 3 Summary of clinical amyloid PET results in brain trauma








impairment (PET at the chronic stage up to
129 months after TBI)
11C-PIB ? in 3/11C-PIB - in 9




11C-PIB in TBI 15, TBI (within 1 year after TBI)
11, HC









18F-florbetapir - in the TBI patient
18F-florbetapir - in the CTE patient, but focal
accumulation at the site of impact in the
occipital region
? Positive scan, - negative scan, HC healthy controls, TBI traumatic brain injury, CTE chronic traumatic encephalopathy
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the TBI and the scan, which is further supported by the
finding of neocortical gray matter plaques found with
immunohistochemistry and 3H-PIB autoradiography per-
formed in the same study in an additional independent
cohort of 16 patients who died between 3 h and 56 days
after TBI. Data also suggested substantial spatial and
temporal variations in binding (Fig. 3), although sample
size and numbers at late time points were too small to draw
robust conclusions, and subjects were not tested longitu-
dinally. Two recently published case reports using 18F-
florbetapir scan in the clinical evaluation of one patient
after 1 year of severe TBI and another patient with CTE,
found negative scan results in both patients [54].
Although the use of amyloid PET in TBI and CTE has
not been yet established, these initial findings suggest that
amyloid PET imaging can offer the opportunity to early
detect the neuropathology during life, and therefore to
understand the pathophysiology of TBI and the mechanistic
drivers of disease progression or suboptimal recovery after
TBI. Identification of different beta-amyloid deposition
patterns may improve etiological likelihood and help in the
differential diagnosis, given the overlap in neurocognitive
and behavioral symptoms across AD, TBI/CTE, and fron-
totemporal dementia [55]. For example, the early binding in
striatum found in Hong et al. [51] is consistent with the
atypical early binding reported in patients with familiar AD
(presenilin-1 mutations), implying worse prognosis than
sporadic forms of AD [23]. Future studies are needed to
determine the influence of age and genetic factors, the
prognostic value of the presence of beta-amyloid in the
brain after TBI, and to longitudinally address the time
course of amyloid deposition and clearance, as well as the
topography of beta-amyloid depositions during life. The
existence and pattern of beta-amyloid depositions over time
in mild TBI, which is difficult to study pathologically in
post-mortem studies, is now possible. Furthermore, amyloid
imaging can contribute to the study of the relationships
between TBI and development of neuropsychological
symptoms, including the risk to develop AD. This will have
a major impact when disease modifying therapies will be
available, allowing to prevent or at least delay the clinical
manifestations of neurodegenerative disease after TBI.
Down’s syndrome
DS is a developmental disorder caused by a chromosome
21 triplication, which leads to an over expression of the
APP gene and cerebral beta-amyloid deposition [56, 57].
Patients with DS have an extremely high incidence of
early-onset AD [58], which has reported to be age depen-
dent. Histopathology studies demonstrate beta-amyloid
plaques in all individuals with DS 40 years and older with
neurofibrillary tangles occurring generally after the age of
40 [59]. The incidence of dementia by age 69 may be as
high as 75 % [60]. The current mean life expectancy of DS
exceeds 50 years, with 20 % or more of the DS population
now aged older than 55 years [61, 62], with the subsequent
Fig. 3 11C-PIB distribution
volume ratio (DVR) maps from
a control and three patients
scanned at different times after
TBI. Note the progressive
decrease in 11C-PIB uptake as
time after TBI increases.
Reproduced from JAMA
Neurol, Hong YT et al. (doi:10.
1001/jamaneurol.2013.4847)
with permission from American
Medical Association
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increase in the incidence of dementia in this population.
Amyloid PET imaging has been used in DS as a model of
the natural history of beta-amyloid deposition in the brain.
Early detection of beta-amyloid deposition using imaging
prior to cognitive symptoms is critical as disease-modify-
ing therapies such as amyloid immunotherapy are devel-
oped [63–65]. Subjects from DS might benefit from novel
anti-amyloid disease modifying drugs, and inclusion of this
population in clinical trials would in addition facilitate
targeting early phases of beta-amyloid deposition.
Beta-amyloid accumulation in DS has been reported in
two PET studies using 11C-PIB PET imaging with limited
sample sizes [66, 67], one study using 18F-florbetaben [68] in
a larger sample, and a case report using 18F-florbetapir [69]
(Table 4). These studies have replicated the finding of an age
dependence of beta-amyloid accumulation in the brain in
DS. In the 11C-PIB studies, which included young and older
DS, all DS subjects 45 years or older (n = 5) [66], and only
the two oldest (38 and 44 years) from seven non-demented
DS [67] showed positive 11C-PIB scans. Positive 18F-florb-
etapir uptake was found in a 55-year-old end of life DS
patient with AD, with post-mortem pathology confirmation
[69]. Using 18F-florbetaben, Jennings et al. [68] reported a
positive correlation between 18F-florbetaben SUVR and age
in non-demented DS subjects. 18F-florbetaben scans were
positive in 7 % of DS aged 40–44 years, in 53 % of DS aged
45–49 years, and in 90 % of DS subjects C50 years. No
relationship with age was found in an independent cohort of
70 young cognitively normal healthy volunteers (range
21–40 years), assumed to be devoid of brain beta-amyloid
Table 4 Summary of clinical amyloid PET results in Down’s syndrome
References Study objective Subject sample (n, clinical diagnosis) Main amyloid PET results
Sabbagh
et al. [69]
18F-florbetapir in end-of-life DS
with neuropathology assessment
(case report)
1, DS with AD (55 years) 18F-florbetapir uptake similar to AD




11C-PIB in DS with and without
AD
9, Mild to moderate demented DS (5
with AD) (25–64 years)
14, HC (33–69 years)




11C-PIB in non-demented young
adults with DS




Correlation of 18F-florbetaben in
DS with age
39, Non-demented DS (40–56 years) Age-dependent 18F-florbetaben ? from 7 % in
4th decade to 90 % in 5th decade
Non-demented DS subjects show 18F-
florbetaben ?
Subtle cognitive changes are associated with
18F-florbetaben uptake
? Positive scan, - negative scan, HC healthy controls, DS Down’s syndrome
Fig. 4 18F-florbetaben SUVR versus age in young cognitively
normal healthy controls (n = 70; SUVR = 0.001 9 age ? 1.173,
R2 = -0.01) (left graph) (Piramal Imaging, unpublished data) and
subjects with Down’s syndrome (n = 39;
SUVR = 0.030 9 age ? 0.045, R2 = 0.39) (middle graph). A graph
showing the percentage of positive 18F-florbetaben scans grouped by
age clusters is shown in the right hand side
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(unpublished data) (Fig. 4). Both visual and quantitative
assessments in the sample of n = 70 healthy volunteers and
n = 39 DS were significantly and strongly related
(v2 = 50.2, p \ 0.0001; Cohen’s j = 0.71), with 92.7 % of
the scans equally classified as positive or negative by both the
visual read and the quantitative approach (SUVR cutoff of
C1.45) (unpublished data). These results provided in vivo
evidence of brain beta-amyloid deposition in non-demented
DS subjects. Moreover, subtle cognitive changes were
associated with beta-amyloid deposition. The topography of
beta-amyloid depositions reported in these PET studies
seems to be overall matching the cortical AD pattern,
although a marked striatal uptake has been found in some DS
subjects [67]. Since striatal uptake has also been reported in
presymptomatic presenilin-1 mutation carriers [23], a link
between beta-amyloid overproduction and early striatal
deposition has been postulated [67].
Altogether, these studies further replicate the ability of
amyloid PET imaging to detect beta-amyloid deposition in
the brain independently of the presence of dementia, and
provide evidence of an age-dependence of beta-amyloid
deposition in DS subjects. Since the incidence of con-
comitant diseases such as vascular dementia is much lower
in DS than in general aged population, the development of
dementia is much more likely to be beta-amyloid driven
[66]. Thus, amyloid PET imaging in this population would
be useful to study the role of the APP and beta-amyloid in
the pathogenesis of AD [70]. Elucidating the interval
between beta-amyloid deposition and the onset of dementia
provides the opportunity to initiate interventions during the
optimal period prior to substantial beta-amyloid deposition
and clinical decline. Longitudinal studies conducted in
individuals with DS would provide crucial data to establish
the association of amyloid deposition with the threshold of
cognitive dysfunction and further enhance our under-
standing of change in beta-amyloid deposition over time.
The higher incidence of dementia in DS as compared to
the general population, the beta-amyloid deposition at
younger ages, and the shortest time of conversion to
dementia make longitudinal studies easier, which are also
needed to determine the potential prognostic value of
amyloid PET imaging in DS.
Meningioma
Two incidental findings of amyloid PET tracer uptake in
meningiomas using PET have been reported [71, 72].
Amyloid stroma in meningiomas has been reported in a
pathology study [73], therefore supporting the hypothesis of
specific binding to amyloid fibrils in these tumors. How-
ever, none of the two reported cases had histologic confir-
mation of amyloid deposition in the lesions. Therefore,
further studies are needed to replicate these findings, con-
firm with pathology, and investigate the mechanism of
amyloid PET tracer binding in meningiomas.
Systemic/cardiac amyloidosis
Amyloidosis is characterized by the extracellular deposi-
tion of insoluble amyloid fibrils in different organs, leading
to progressive organ dysfunction. In AD, the brain is
affected. However, in systemic amyloidosis the brain is
almost always spared, but any other organ (e.g. lungs, liver,
kidneys, bones, etc.) can be affected. The disease is life-
threatening and of insidious nature, thus diagnosis is fre-
quently delayed. Advanced organ dysfunction is usually
present at the time of diagnosis. Heart involvement, leading
to cardiac insufficiency or arrhythmias, is the main cause of
mortality and morbidity in amyloidosis, and is a differen-
tial diagnosis of heart failure. Several types of amyloid can
infiltrate the heart, but the most frequent ones are systemic
light chain (AL) and transthyretin (ATTR, wild type or
mutant) amyloidosis [74], which have different clinical,
therapeutic and prognostic implications. Cardiac AL
amyloidosis is characterized by a rapidly progressive
clinical course and high mortality, while ATTR wild-type
disease (senile amyloidosis) typically has a slower clinical
course with a much longer overall survival [75]. Although
non-invasive imaging techniques such as echocardiography
and MRI can support the diagnosis, the findings are non-
specific and can be found in other cardiac diseases. Clinical
manifestations also overlap with other heart diseases, and
diagnosis is made in an advanced stage, when anatomic
changes have occurred and response to therapy is slow and
not easily measurable [76]. The definitive diagnosis
requires endomyocardial biopsy with immunohistochem-
istry or mass spectroscopy to identify the type of amyloi-
dosis. However, this is an invasive procedure with high risk
of complications, and sampling errors and the lack of
information about amyloid distribution, extent and pro-
gression are limitations. Therefore, non-invasive diagnostic
tools allowing early detection, quantitative assessment and
distribution of amyloid proteins, and monitoring disease
progression and response to treatments are needed. Ability
to identify potential amyloid deposition in several organs
(whole body imaging) is an additional advantage. Despite
SPECT imaging of CA has also been investigated (for a
review, see [77]), amyloid PET may be the nuclear imaging
diagnostic modality of choice in the future, given the
higher resolution of PET and the high target selectivity of
amyloid PET tracers, together with the growing availability
of PET in most nuclear medicine departments.
However, there is still limited evidence pointing to a
potential utility of amyloid PET imaging in CA. In our
48 Clin Transl Imaging (2015) 3:39–55
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search, only two original studies were found, one using
11C-PIB [78], another using 18F-florbetapir [76] (Table 5).
Both included limited sample of subjects, but results were
quite in agreement. Independency of tracer uptake from
blood flow was shown in Antoni et al. [78], and both
studies reported a diffuse uptake that was significantly
higher in patients, and higher amyloid tracer uptake rela-
tive to blood flow (Fig. 5). Both tracers seem to bind to
Table 5 Summary of clinical amyloid PET results in cardiac amyloidosis
References Study objective Subject sample (n, clinical
diagnosis)
Main amyloid PET results
Antoni et al.
[78]
11C-PIB in CA 10, CA (AL and ATTR)
5, HC
11C-PIB ? in all CA patients
11C-PIB - in all HC
Significant difference in 11C-PIB uptake in the heart between patients
and controls
No correlation between PIB and myocardial blood flow
Dorbala et al.
[76]
18F-florbetapir in CA 9, CA (5 AL and 4 ATTR)
5, HC
18F-florbetapir ? in all CA patients
18F-florbetapir - in all HC
Trend to a higher uptake in the AL subjects compared to the ATTR
subjects without reaching statistical significance
Minamimoto
et al. [80]




11C-PIB ? in brain
11C-PIB – in heart, 99mTc-aprotinin ? in heart
Lhommel
et al. [79]
Case report with 18F-
flutemetamol
1, Well documented cardiac
AL amyloidosis
1, HC
18F-flutemetamol ? in myocardium compared with no uptake in the
heart of the HC
? Positive scan, - negative scan, HC healthy controls, CA cardiac amyloidosis, AL light chain amyloidosis, ATTR transthyretin amyloidosis
Fig. 5 Short-axis images of 11C-PIB retention index (RI) and
myocardial blood flow (MBF) in (left to right) patients with high,
intermediate, and partially increased 11C-PIB retention and a healthy
control. Liver is clearly visible in 11C-PIB images of one patient
(second column images) patient and healthy control, and is just
outside PET field of view for other two patients. Liver uptake is due
to biliary excretion of 11C-PIB and is likely not related to amyloid
binding. This research was originally published in JNM. Antoni et al.
[78]  by the Society of Nuclear Medicine and Molecular Imaging,
Inc
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amyloid fibrils of any type, since cardiac uptake was
detected in all patients independently of the type of amy-
loidosis (AL or ATTR). A trend to higher uptake in AL was
described in Antoni et al. [78], but no specific comparison
between AL and ATTR was made in Dorbala et al. [76].
Distribution of tracer uptake seems to be homogeneous in
all cases, including uptake in left and right ventricles and
atriums. Local accumulation of tracer in the septum was
reported in one of the patients in each study. Quantification
was performed by using SUV, target to background ratio,
and myocardial retention index (myocardial tissue radio-
tracer concentration divided by the integral of the blood
pool time–activity curve from 0 to 20 min after injection).
A threshold to separate patients from controls was found in
Dorbala et al. [76]. Diffuse bilateral 18F-florbetapir uptake
in the lungs of a patient with AL amyloidosis of the lungs
and pleural effusions, but not in another patient with ATTR
congestive heart failure and pleural effusions was reported
[76]. Antoni et al. [78] found no significant differences
between patients with and without melphalan treatment
(6–54 months before PET). Myocardial uptake with 18F-
flutemetamol has also been reported in a case report of a
56-year-old patient with well documented cardiac AL
amyloidosis, compared to no myocardial uptake in an
elderly healthy control [79]. In contrast, an amyloid cardiac
imaging mismatch between 99mTc-aprotinin SPECT
(positive) and 11C-PIB PET (negative) was reported in a
82-year-old patient with suspected CA who showed 11C-
PIB positive brain scan [80] (Table 5).
These preliminary results suggest that amyloid PET can
have potential utility in CA. Replication of these findings are
needed from studies in larger sample sizes, including con-
trols with heart failure to evaluate usefulness in this current
differential diagnosis need. Studies powered to investigate
the possibility to differentiate between AL and ATTR CA,
which have different prognosis and therapies are also
required. Selectivity of different amyloid PET tracer binding
sites for each type of amyloidosis from pathology studies,
potential clinical implications of the pattern of accumulation
in different regions of the heart, as well as influence of
therapy in the uptake pattern are still to be investigated.
Amyloid PET imaging as myelin biomarker
All amyloid PET tracers show binding to the WM in more
or less degree, independently of the presence or absence
of cortical beta-amyloid deposition (positive and negative
scans, respectively). The mechanism of this binding is
poorly understood, and it is considered to be non-specific,
mainly due to the non-displaceable and non-saturable
characteristics, which have been reported using 11C-PIB
[81, 82]. The high lipid content of the WM and the
lipophilic nature of the amyloid PET tracers can con-
tribute to this non-specific binding. The hypothesis that
amyloid PET tracers could bind to myelin has been
investigated and led to controversial results in in vitro
studies using 11C-PIB autoradiography and autofluores-
cence in human brain tissue, some supporting staining or
binding in WM tracts [83] but not others [82]. Given that
some Congo red derivatives originally described as amy-
loid PET markers show affinity for myelin, it has been
suggested that the beta-sheet structure that is present in
both the AD amyloid peptide and in the myelin binding
protein, which is a major protein component of myelin,
can be a common target for amyloid PET tracers [82–85].
Hence, there is increasing interest in investigating whether
amyloid PET imaging could be a suitable biomarker for
WM and myelin lesions, and therefore be potentially
useful in detecting WM lesions and demyelination–re-
myelination processes as occur in MS. Again, there is
very limited experience in this regard (Table 6). Stankoff
et al. [83] reported average 30 % (5–57 %) reduction in
11C-PIB uptake compared to the adjacent normal-appear-
ing WM, in a total of eight demyelinated lesions in two
patients with relapsing-remitting MS. The high variation
in the reduced 11C-PIB uptake among lesions was con-
sistent with the different degrees of demyelination iden-
tified in MRI T2 sequences [86]. Interestingly, the
decreased uptake was higher in MRI (3D MP-RAGE)
non-active than in active lesions, suggesting that gado-
linium-enhanced lesions are less demyelinated (Fig. 6).
Glodzik et al. [87] reported a significant mean of 14 %
reduction in 11C-PIB uptake in WM lesions than in
Table 6 Summary of clinical amyloid PET results in myelin lesions
References Study objective Subject sample (n, clinical
diagnosis)
Main amyloid PET results
Stankoff et al.
[84]
11C-PIB as a myelin
marker
2, MS (relapsing remitting) 11C-PIB uptake reduction (5-57 %) in MS lesions







Reduced 11C-PIB uptake in white matter lesions compared to normal
appearance white matter
? Positive scan, - negative scan, MS multiple sclerosis
50 Clin Transl Imaging (2015) 3:39–55
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normal-appearing WM defined by FLAIR MRI in a group
of 73 cognitively healthy elderly subjects. The reduced
uptake was higher in periventricular WM lesions (17.8 %)
than in deep WM lesions (7.5 %), in consistency with the
greater myelin binding protein loss reported using
immunohistochemistry in periventricular WM lesions
[88]. Although these are very preliminary results, it has
been postulated that the lower reduction percentages
found in WM lesions from elderly subjects compared to
MS patients may indicate that demyelination associated
with age is less pronounced than in MS.
A surrogate marker to assess potential therapies in MS,
by identifying the demyelination–remyelination process in
the different brain lesions is an unmet need. These initial,
preliminary results reported to date with amyloid PET
imaging are promising. However, replication of these
findings in studies with larger patient samples and different
amyloid tracers are still needed. Scanner resolution limi-
tations in the detection of small size lesions, MRI
sequences used to identify lesions, region of interest
method to quantify tracer uptake in PET images, potential
partial volume effects, and effects of blood–brain barrier
Fig. 6 MP-RAGE 3T MRI (a,
d, f) and corresponding co-
registered 11C-PIB slices (b, c,
e, g) from two representative
patients from Stankoff et al.
[83] (d–g correspond to the
same patient). c Shows
superposition of MRI and PET
images. Arrows point to MA
plaques, and arrowheads point
to gray matter structures, both
appearing as a loss of uptake on
PET images. Reproduced from
Ann Neurol, Stankoff et al. [83]
with permission from the
American Neurological
Association
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disruption or blood flow influence are methodological
challenges to be overcome in future studies.
Conclusion
Investigation of amyloid PET imaging beyond AD is
subject of current active research. Amyloid PET imaging
offers a unique possibility to explore the relationships
between beta-amyloid depositions and clinical outcomes
during life. As it happens in AD, for non-AD diseases
where brain amyloid is present and may be involved in the
disease pathogenesis (e.g. DLB, TBI/CTE, CAA, DS),
development of efficacious disease-modifying drugs will
be needed in order to have a direct impact in patient
treatment. In the meanwhile, the major clinical benefit in
these cases would be related to early identification and
most likely prognosis. Longitudinal studies are clearly
needed to progress in this direction. Despite the good
correlation between visual assessments and quantitative
PET measurements, amyloid PET quantification becomes
crucial for assessing changes in brain amyloid load over
time, as well as for some research purposes, e.g. patient
group comparisons or relationships with clinical features.
Current evidence of the potential usefulness of amyloid
PET imaging in CA and MS is very limited. However, if
the reported results are confirmed in future studies, thera-
peutic implications of amyloid PET imaging would be of
immediate application in CA, since treatments are already
available and both therapy and prognosis are different for
AL and ATTR types. Early diagnosis would also have
beneficial impact in treatment efficacy. Similarly, an
accurate and prompt identification of the demyelination–
remyelination process in cerebral lesions by a non-invasive
myelin biomarker would improve management of patients
with MS.
The potential clinical implications of different patterns
of regional brain amyloid PET tracer uptake deserve fur-
ther investigation, as the localization of brain beta-amyloid
depositions is a unique benefit of amyloid PET imaging
compared with other pathology biomarkers such as cere-
brospinal fluid or blood tests. Most of the currently avail-
able data has been obtained using 11C-PIB. Further studies
replicating 11C-PIB findings using 18F-labeled amyloid
tracers, with larger sample sizes, and designed to overcome
the limitations identified to date in the process, are needed
and would be an important step towards the extended
clinical use of amyloid PET imaging in clinical practice.
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